Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis

  • China National Medical Products Administration (NMPA) approval reinforces that Cosentyx® (secukinumab) is safe and effective for children and adults with psoriasis
  • Moderate-to-severe plaque psoriasis affects more than 350,000 children worldwide1, with the physical and psychological burden disrupting important formative years2
  • Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory …
/by

Novartis announces positive results from Phase III trials of Beovu® in diabetic macular edema, including dosing intervals up to 16 weeks

  • Results from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2
  • In key fluid-related secondary endpoints from KITE at year two, Beovu® (brolucizumab) 6 mg demonstrated greater reductions in central subfield thickness, and fewer patients had intraretinal and/or subretinal fluid versus aflibercept1
  • A majority of patients who …
/by